Investors
Oxurion/Investors/News/Oxurion to make a late-breaker presentation of topline TH…

Oxurion to make a late-breaker presentation of topline THR-149 (Plasma Kallikrein inhibitor) Phase 1 clinical data at EURETINA 2019

2 Sep 2019General

Documents

English
Download PDF

Back to news